Alphatec Refinances Debt, Q1 EBITDA Beats Estimates Despite Revenue Miss
ATEC is trading near its 52-week low of $9.11 (12% below the low) on elevated volume (2.8× avg).
Summary
Alphatec Holdings reported Q1 revenue of $192 million, a 14% year-over-year increase, but missed analyst estimates of $197.35 million. Despite the revenue miss, the company beat adjusted EBITDA estimates, reporting $21 million against a consensus of $19.83 million, with margin expanding to 11%. Crucially, Alphatec also announced the refinancing of existing debt, which is expected to reduce annual interest expense by over $6 million and extend maturities to 2031. This follows the company's strong full-year 2025 results, which also highlighted a major debt refinancing. The revenue miss is a negative, but it is significantly mitigated by the adjusted EBITDA beat and the material improvement to the company's financial structure through the debt refinancing. Maintaining full-year guidance despite the Q1 revenue miss also signals management's confidence. Investors will monitor future revenue growth rates and the continued impact of the debt refinancing on the balance sheet.
At the time of this announcement, ATEC was trading at $8.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $9.11 to $23.29. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.